Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 845 entries
Sorted by: Best Match Show Resources per page
Amiodarone Induced Thyrotoxicosis - Fluctuating RVOT and LV Scar VT.

Journal of atrial fibrillation

Pillarisetti J, Vanga SR, Lakkireddy D.
PMID: 28496802
J Atr Fibrillation. 2013 Feb 12;5(5):342. doi: 10.4022/jafib.342. eCollection 2013.

A 61 year old patient with non-ischemic cardiomyopathy and implantable cardioverter defibrillator presented with multiple shocks for ventricular tachycardia (VT). EKG revealed monomorphic sustained VT which was left bundle inferior axis that spontaneously changed into sustained VT which was...

Cite
Pillarisetti J, Vanga SR, Lakkireddy D. Amiodarone Induced Thyrotoxicosis - Fluctuating RVOT and LV Scar VT. J Atr Fibrillation. 2013;5(5):342doi: 10.4022/jafib.342.
Pillarisetti, J., Vanga, S. R., & Lakkireddy, D. (2013). Amiodarone Induced Thyrotoxicosis - Fluctuating RVOT and LV Scar VT. Journal of atrial fibrillation, 5(5), 342. https://doi.org/10.4022/jafib.342
Pillarisetti, Jayasree, et al. "Amiodarone Induced Thyrotoxicosis - Fluctuating RVOT and LV Scar VT." Journal of atrial fibrillation vol. 5,5 (2013): 342. doi: https://doi.org/10.4022/jafib.342
Pillarisetti J, Vanga SR, Lakkireddy D. Amiodarone Induced Thyrotoxicosis - Fluctuating RVOT and LV Scar VT. J Atr Fibrillation. 2013 Feb 12;5(5):342. doi: 10.4022/jafib.342. eCollection 2013. PMID: 28496802; PMCID: PMC5153097.
Copy Download .nbib Format: NLM
Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedarone versus Amiodarone and Other Antiarrhythmics.

Journal of atrial fibrillation

Gao S, Dai W, Zhang L, Juhaeri J, Wang Y, Caubel P.
PMID: 28496906
J Atr Fibrillation. 2013 Dec 31;6(4):890. doi: 10.4022/jafib.890. eCollection 2013 Dec.

No published studies have evaluated the risks of cardiovascular (CV) events, stroke, congestive heart failure (CHF), interstitial lung disease (ILD), and severe acute liver injury (ALI) related to antiarrhythmics treatment in real-world clinical practice setting. We examined the relationship...

Cite
Gao S, Dai W, Zhang L, et al. Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedarone versus Amiodarone and Other Antiarrhythmics. J Atr Fibrillation. 2013;6(4):890doi: 10.4022/jafib.890.
Gao, S., Dai, W., Zhang, L., Juhaeri, J., Wang, Y., & Caubel, P. (2013). Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedarone versus Amiodarone and Other Antiarrhythmics. Journal of atrial fibrillation, 6(4), 890. https://doi.org/10.4022/jafib.890
Gao, Shujun, et al. "Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedarone versus Amiodarone and Other Antiarrhythmics." Journal of atrial fibrillation vol. 6,4 (2013): 890. doi: https://doi.org/10.4022/jafib.890
Gao S, Dai W, Zhang L, Juhaeri J, Wang Y, Caubel P. Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedarone versus Amiodarone and Other Antiarrhythmics. J Atr Fibrillation. 2013 Dec 31;6(4):890. doi: 10.4022/jafib.890. eCollection 2013 Dec. PMID: 28496906; PMCID: PMC5153130.
Copy Download .nbib Format: NLM
Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients.

Journal of pharmaceutical health care and sciences

Komatsu T, Morita M, Miyaji F, Inomata T, Ako J, Atsuda K.
PMID: 26819736
J Pharm Health Care Sci. 2015 Sep 25;1:25. doi: 10.1186/s40780-015-0023-6. eCollection 2015.

BACKGROUND: This study aimed to evaluate the population pharmacokinetics of digoxin in Japanese patients and establish a dosage regimen based on the pharmacokinetic data.METHODS: We analyzed 287 serum digoxin samples from 192 individuals by using the nonlinear mixed effects...

Cite
Komatsu T, Morita M, Miyaji F, et al. Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients. J Pharm Health Care Sci. 2015;1:25doi: 10.1186/s40780-015-0023-6.
Komatsu, T., Morita, M., Miyaji, F., Inomata, T., Ako, J., & Atsuda, K. (2015). Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients. Journal of pharmaceutical health care and sciences, 125. https://doi.org/10.1186/s40780-015-0023-6
Komatsu, Toshiaki, et al. "Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients." Journal of pharmaceutical health care and sciences vol. 1 (2015): 25. doi: https://doi.org/10.1186/s40780-015-0023-6
Komatsu T, Morita M, Miyaji F, Inomata T, Ako J, Atsuda K. Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients. J Pharm Health Care Sci. 2015 Sep 25;1:25. doi: 10.1186/s40780-015-0023-6. eCollection 2015. PMID: 26819736; PMCID: PMC4728823.
Copy Download .nbib Format: NLM
Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial.

Emergency (Tehran, Iran)

Shojaee M, Feizi B, Miri R, Etemadi J, Feizi AH.
PMID: 28286836
Emerg (Tehran). 2017;5(1):e29. Epub 2017 Jan 10.

INTRODUCTION: Treatment of rapid ventricular response arterial fibrillation (rapid AF) varies depending on the decision of the in-charge physician, condition of the patient, availability of the drug, and the treatment protocol of the hospital. The present study was designed...

Cite
Shojaee M, Feizi B, Miri R, et al. Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial. Emerg (Tehran). 2017;5(1):e29
Shojaee, M., Feizi, B., Miri, R., Etemadi, J., & Feizi, A. H. (2017). Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial. Emergency (Tehran, Iran), 5(1), e29.
Shojaee, Majid, et al. "Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial." Emergency (Tehran, Iran) vol. 5,1 (2017): e29.
Shojaee M, Feizi B, Miri R, Etemadi J, Feizi AH. Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial. Emerg (Tehran). 2017;5(1):e29. Epub 2017 Jan 10. PMID: 28286836; PMCID: PMC5325898.
Copy Download .nbib Format: NLM
Amiodarone-Associated Optic Neuropathy: Clinical Review.

Neuro-ophthalmology (Aeolus Press)

Wang AG, Cheng HC.
PMID: 28348626
Neuroophthalmology. 2016 Nov 18;41(2):55-58. doi: 10.1080/01658107.2016.1247461. eCollection 2017 Apr.

Amiodarone, an antiarrhythmic agent, has been associated with visual loss secondary to optic neuropathy. The reported mean duration of amiodarone use before visual loss is about 9 months. Patients receiving amiodarone have a 2-fold increased risk of developing optic...

Cite
Wang AG, Cheng HC. Amiodarone-Associated Optic Neuropathy: Clinical Review. Neuroophthalmology. 2016;41(2):55-58doi: 10.1080/01658107.2016.1247461.
Wang, A. G., & Cheng, H. C. (2017). Amiodarone-Associated Optic Neuropathy: Clinical Review. Neuro-ophthalmology (Aeolus Press), 41(2), 55-58. https://doi.org/10.1080/01658107.2016.1247461
Wang, An-Guor, and Cheng, Hui-Chen. "Amiodarone-Associated Optic Neuropathy: Clinical Review." Neuro-ophthalmology (Aeolus Press) vol. 41,2 (2017): 55-58. doi: https://doi.org/10.1080/01658107.2016.1247461
Wang AG, Cheng HC. Amiodarone-Associated Optic Neuropathy: Clinical Review. Neuroophthalmology. 2016 Nov 18;41(2):55-58. doi: 10.1080/01658107.2016.1247461. eCollection 2017 Apr. PMID: 28348626; PMCID: PMC5354097.
Copy Download .nbib Format: NLM
Idiopathic Giant Cell Myocarditis.

Current treatment options in cardiovascular medicine

Cooper LT, Okura Y.
PMID: 11696266
Curr Treat Options Cardiovasc Med. 2001 Dec;3(6):463-467. doi: 10.1007/s11936-001-0020-y.

Idiopathic giant cell myocarditis (IGCM) is an uncommon disorder that is of general importance because it most commonly affects young individuals, is usually fatal without treatment, and may respond to aggressive medical and surgical therapy. IGCM is most often...

Cite
Cooper LT, Okura Y. Idiopathic Giant Cell Myocarditis. Curr Treat Options Cardiovasc Med. 2001;3(6):463-467doi: 10.1007/s11936-001-0020-y.
Cooper, L. T., & Okura, Y. (2001). Idiopathic Giant Cell Myocarditis. Current treatment options in cardiovascular medicine, 3(6), 463-467. https://doi.org/10.1007/s11936-001-0020-y
Cooper, Leslie T., and Okura, Yuji. "Idiopathic Giant Cell Myocarditis." Current treatment options in cardiovascular medicine vol. 3,6 (2001): 463-467. doi: https://doi.org/10.1007/s11936-001-0020-y
Cooper LT, Okura Y. Idiopathic Giant Cell Myocarditis. Curr Treat Options Cardiovasc Med. 2001 Dec;3(6):463-467. doi: 10.1007/s11936-001-0020-y. PMID: 11696266.
Copy Download .nbib Format: NLM
Respiratory and Hemodynamic Management After Cardiac Surgery.

Current treatment options in cardiovascular medicine

Liu LL, Gropper MA.
PMID: 11858778
Curr Treat Options Cardiovasc Med. 2002 Apr;4(2):161-169. doi: 10.1007/s11936-002-0036-y.

In this new era of managed care, the emphasis has been on the reduction of intensive-care stay after coronary artery bypass surgery. "Fast-track" or rapid weaning protocols have become increasingly popular due to evidence that shows their cost-effectiveness and...

Cite
Liu LL, Gropper MA. Respiratory and Hemodynamic Management After Cardiac Surgery. Curr Treat Options Cardiovasc Med. 2002;4(2):161-169doi: 10.1007/s11936-002-0036-y.
Liu, L. L., & Gropper, M. A. (2002). Respiratory and Hemodynamic Management After Cardiac Surgery. Current treatment options in cardiovascular medicine, 4(2), 161-169. https://doi.org/10.1007/s11936-002-0036-y
Liu, Linda L., and Gropper, Michael A.. "Respiratory and Hemodynamic Management After Cardiac Surgery." Current treatment options in cardiovascular medicine vol. 4,2 (2002): 161-169. doi: https://doi.org/10.1007/s11936-002-0036-y
Liu LL, Gropper MA. Respiratory and Hemodynamic Management After Cardiac Surgery. Curr Treat Options Cardiovasc Med. 2002 Apr;4(2):161-169. doi: 10.1007/s11936-002-0036-y. PMID: 11858778.
Copy Download .nbib Format: NLM
Recurrent Torsades de Pointes After Sotalol Therapy for Symptomatic Paroxysmal Atrial Fibrillation in a Patient with End-Stage Renal Disease.

Journal of cardiovascular pharmacology and therapeutics

Rizza C, Valderrabano M, Singh BN.
PMID: 10684532
J Cardiovasc Pharmacol Ther. 1999 Apr;4(2):129-134. doi: 10.1177/107424849900400208.

BACKGROUND: In recent years there has been ain increase in the use of class III antiarrhythmic drugs such as sotalol, amiodarone, and the so-called pure class III compound for the control of cardiac arrhythmias. It appears there has been...

Cite
Rizza C, Valderrabano M, Singh BN. Recurrent Torsades de Pointes After Sotalol Therapy for Symptomatic Paroxysmal Atrial Fibrillation in a Patient with End-Stage Renal Disease. J Cardiovasc Pharmacol Ther. 1999;4(2):129-134doi: 10.1177/107424849900400208.
Rizza, C., Valderrabano, M., & Singh, B. N. (1999). Recurrent Torsades de Pointes After Sotalol Therapy for Symptomatic Paroxysmal Atrial Fibrillation in a Patient with End-Stage Renal Disease. Journal of cardiovascular pharmacology and therapeutics, 4(2), 129-134. https://doi.org/10.1177/107424849900400208
Rizza, et al. "Recurrent Torsades de Pointes After Sotalol Therapy for Symptomatic Paroxysmal Atrial Fibrillation in a Patient with End-Stage Renal Disease." Journal of cardiovascular pharmacology and therapeutics vol. 4,2 (1999): 129-134. doi: https://doi.org/10.1177/107424849900400208
Rizza C, Valderrabano M, Singh BN. Recurrent Torsades de Pointes After Sotalol Therapy for Symptomatic Paroxysmal Atrial Fibrillation in a Patient with End-Stage Renal Disease. J Cardiovasc Pharmacol Ther. 1999 Apr;4(2):129-134. doi: 10.1177/107424849900400208. PMID: 10684532.
Copy Download .nbib Format: NLM
Role of vitamin-E on rat liver-amiodarone: an ultrastructural study.

Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association

Zaki MS, Eid RA.
PMID: 19568574
Saudi J Gastroenterol. 2009 Apr;15(2):104-10. doi: 10.4103/1319-3767.48967.

BACKGROUND/AIM: Amiodarone, a class III antiarrhythmic drug, has been found to be effective in the management of patients with life-threatening ventricular arrhythmias. The aim of this study was to test whether the co administration of vitamin-E with amiodarone can...

Cite
Zaki MS, Eid RA. Role of vitamin-E on rat liver-amiodarone: an ultrastructural study. Saudi J Gastroenterol. 2009;15(2):104-10doi: 10.4103/1319-3767.48967.
Zaki, M. S., & Eid, R. A. (2009). Role of vitamin-E on rat liver-amiodarone: an ultrastructural study. Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association, 15(2), 104-10. https://doi.org/10.4103/1319-3767.48967
Zaki, Mohamed Samir A, and Eid, Refaat A. "Role of vitamin-E on rat liver-amiodarone: an ultrastructural study." Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association vol. 15,2 (2009): 104-10. doi: https://doi.org/10.4103/1319-3767.48967
Zaki MS, Eid RA. Role of vitamin-E on rat liver-amiodarone: an ultrastructural study. Saudi J Gastroenterol. 2009 Apr;15(2):104-10. doi: 10.4103/1319-3767.48967. PMID: 19568574; PMCID: PMC2702968.
Copy Download .nbib Format: NLM
Dronedarone (Sanofi-Synthélabo).

IDrugs : the investigational drugs journal

Le Grand B.
PMID: 16012904
IDrugs. 2001 May;4(5):582-5.

Sanofi-Synthelabo (formerly Sanofi) is developing the class III antiarrhythmic agent, dronedarone, for the potential treatment of atrial fibrillation and ventricular tachycardia [157842]. Phase III trials for the treatment of arrhythmia are planned for 2001 [399945]. By December 1998, phase...

Cite
Le Grand B. Dronedarone (Sanofi-Synthélabo). IDrugs. 2001;4(5):582-5
Le Grand, B. (2001). Dronedarone (Sanofi-Synthélabo). IDrugs : the investigational drugs journal, 4(5), 582-5.
Le Grand, B. "Dronedarone (Sanofi-Synthélabo)." IDrugs : the investigational drugs journal vol. 4,5 (2001): 582-5.
Le Grand B. Dronedarone (Sanofi-Synthélabo). IDrugs. 2001 May;4(5):582-5. PMID: 16012904.
Copy Download .nbib Format: NLM
An implantable cardioverter-defibrillator but not amiodarone reduced risk for death in congestive heart failure.

ACP journal club

Corsello A.
PMID: 15989294
ACP J Club. 2005 Jul-Aug;143(1):6.

No abstract available.

Cite
Corsello A. An implantable cardioverter-defibrillator but not amiodarone reduced risk for death in congestive heart failure. ACP J Club. 2005;143(1):6
Corsello, A. (2005). An implantable cardioverter-defibrillator but not amiodarone reduced risk for death in congestive heart failure. ACP journal club, 143(1), 6.
Corsello, Andrew. "An implantable cardioverter-defibrillator but not amiodarone reduced risk for death in congestive heart failure." ACP journal club vol. 143,1 (2005): 6.
Corsello A. An implantable cardioverter-defibrillator but not amiodarone reduced risk for death in congestive heart failure. ACP J Club. 2005 Jul-Aug;143(1):6. PMID: 15989294.
Copy Download .nbib Format: NLM
Amiodarone reduced the risk of resuscitated ventricular fibrillation or arrhythmic death in survivors of MI with frequent or repetitive ventricular premature depolarizations.

Evidence-based cardiovascular medicine

Brent Mitchell L.
PMID: 16379736
Evid Based Cardiovasc Med. 1997 Sep;1(3):75-6. doi: 10.1016/s1361-2611(97)80064-4.

No abstract available.

Cite
Brent Mitchell L. Amiodarone reduced the risk of resuscitated ventricular fibrillation or arrhythmic death in survivors of MI with frequent or repetitive ventricular premature depolarizations. Evid Based Cardiovasc Med. 1997;1(3):75-6doi: 10.1016/s1361-2611(97)80064-4.
Brent Mitchell, L. (1997). Amiodarone reduced the risk of resuscitated ventricular fibrillation or arrhythmic death in survivors of MI with frequent or repetitive ventricular premature depolarizations. Evidence-based cardiovascular medicine, 1(3), 75-6. https://doi.org/10.1016/s1361-2611(97)80064-4
Brent Mitchell, L. "Amiodarone reduced the risk of resuscitated ventricular fibrillation or arrhythmic death in survivors of MI with frequent or repetitive ventricular premature depolarizations." Evidence-based cardiovascular medicine vol. 1,3 (1997): 75-6. doi: https://doi.org/10.1016/s1361-2611(97)80064-4
Brent Mitchell L. Amiodarone reduced the risk of resuscitated ventricular fibrillation or arrhythmic death in survivors of MI with frequent or repetitive ventricular premature depolarizations. Evid Based Cardiovasc Med. 1997 Sep;1(3):75-6. doi: 10.1016/s1361-2611(97)80064-4. PMID: 16379736.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 845 entries